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FibrosisEndogenous cardiotonic steroids (CTS), also called digitalis like factors, have been postulated to play
important roles in pathogenesis of hypertension for nearly half of a century. For the past 50 years biomedical
scientists have been in quest of an unidentiﬁed factor or hormone that both increases blood pressure and
renal sodium excretion; this “natriuretic hormone”was, in fact, postulated to interact with the Na/K-ATPase.
Recent discoveries have led to the identiﬁcation of steroid molecules which are present in humans, rodents
and amphibians, and which, in a complex manner, interact with each other and with the other systems that
regulate renal salt handling and contribute to the salt-sensitivity of blood pressure.
Recent ﬁndings include the speciﬁc identiﬁcation of endogenous cardenolide (endogenous ouabain) and
bufadienolide (marinobufagenin) CTS in humans along with the delineation of mechanisms by which CTS can
signal through the Na/K-ATPase. Although CTSwere ﬁrst considered important in the regulation of renal sodium
transport and arterial pressure, more recent work implicates these hormones in the central regulation of blood
pressure and regulation of cell growth, and development of cardiovascular and renal ﬁbrosis in particular.Science, National Institute on
21224, USA. Tel.: +1 410 558
.
B.V.Published by Elsevier B.V.1. Concept of natriuretic hormone
The NaCl-sensitivity of blood pressure is thought to be due, at least
in part, to a compromised ability of the kidneys to excrete sodium,
which is mediated by variety of factors, both genetic and environ-
mental [1]. One of such factors are endogenous digitalis-like inhibitors
of the Na/K-ATPase, or cardiotonic steroids (CTS) [2].
Lewis Dahl was one of the ﬁrst to hypothesize that salt-induced
hypertension may be mediated by a humoral factor, which raises the
blood pressure [3]. Based on numerous observations made in human
subjects and in experimental animals under the conditions of NaCl
loading and volume expansion, deWardener and others [2] postulated
that a humoral prohypertensive factor implicated in the pathogenesis of
NaCl-sensitive hypertension is an endogenous natriuretic. Because Na/
K-ATPase comprises a major sodium transporting mechanism in the
kidney, and because digitalis glycosides are speciﬁc ligands of theNa/K-
ATPase, it has been further postulated that a putative natriuretic
hormone has digitalis-like properties. According to the “concept of
natriuretic hormone,” the primary role of endogenous digitalis is to
promote natriuresis via inhibition of the Na/K-ATPase and sodiumreabsorption in the renal proximal tubules [2]. The increased plasma
levels of digitalis-like CTS could also contribute to vasoconstriction via
inhibition of the Na,K-pump, coupled with activation of Na+/Ca2+
exchange in vascular smoothmuscle [4]. In accordwith these views,Na/
K-ATPase activity in the cardiovascular tissues from dogs and rats with
low renin hypertension was found to be decreased [5,6], and plasma
saline volume expansion of dogswas shown to raise levels of circulating
digoxin-like immunoreactive material [7]. Subsequently, Hamlyn et al.
demonstrated that plasma Na/K-ATPase inhibitory activity is positively
associatedwith blood pressure in hypertensive patients [8]. Kojima et al
[9] showed that anti-digoxin antibody lowers blood pressure in rats
with deoxycorticosterone-salt-induced hypertension. These ﬁndings
prompted search for the identity of “endogenous digitalis.”2. Endogenous ouabain
Endogenous ouabain (EO) was the ﬁrst CTS to be identiﬁed in
human plasma [10,11], but in humans EO did not appear to be
natriuretic, and peripheral levels of this hormone were not stimulated
by chronic high NaCl intake [12]. In rats, ouabain exhibits high afﬁnity
for theα2/α3 isoforms of Na/K-ATPase [13], while tubular cells of the
rat kidney, the target for a “natriuretic hormone,” express mainly the
α1 isoform, which is relatively insensitive to ouabain [14]. Although
EO does not fulﬁll the criteria for a putative natriuretic hormone,
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pathogenesis of NaCl-sensitive hypertension.
Experimental studies performed by Takahashi's group demon-
strated that in normotensive Wistar rats and in rats with DOCA-NaCl
hypertension central administration of low concentrations of ouabain
elicits pressor and natriuretic which are dependent on the activation
of renin–angiotensin system [15,16]. Subsequently, the same group
demonstrated that development of DOCA-salt hypertension is
associated with increases in the levels of two different CTS, in the
brain and in the adrenal cortex [17]. Later, in Leenen's laboratory, in
three strains of rats, in Dahl salt-sensitive (DS), Wistar, and
spontaneously hypertensive rats, brain EOwas found to be responsive
to acute and chronic NaCl loading [18]. Notably, pressor responses to
central administration of ouabain and to NaCl were shown to
stimulate brain EO levels via activation of central RAAS [19,20]. In
DS, NaCl-induced activation of brain EO was accompanied by an
increase in plasma Na/K-ATPase inhibitory activity in presence of
unchanged plasma levels of ouabain-like immunoreactivity, suggest-
ing that CTS other than EO were involved in these events [21,22].
3. Endogenous bufadienolides
For centuries it had been known that the skin and parotid gland of
several amphibian species contain substantial amounts of bufadieno-
lides, CTSwhichdiffer fromcardenolides, suchasdigoxinandouabain, in
having a doubly unsaturated six-membered lactone ring [23]. Since
antiquity bufadienolides from amphibian skin have been used in
traditional Oriental medicine to treat cardiac failure [23]. Considering
that in amphibia, skin participates in the regulation ofwater/electrolyte
homeostasis, it was hypothesized that the Na/K-ATPase and bufadie-
nolides represent a system which regulates water/electrolyte balance,
i.e. that bufadienolides function as the putativemammalian “natriuretic
hormone” [24]. Accordingly, the highest levels of bufadienolides were
found in those amphibian species which migrate from dry to aquatic
environment [25]. Later, in agreement with this hypothesis, brain and
skin levels of bufadienolides in the toads were shown to change
according to the changes in environmental salinity [26].
Shortly thereafter, several groups demonstrated that human ﬂuids
contain material which cross-react with antibodies against one of the
bufadienolides, bufalin [27–29]. Later, Lichtstein et al. [30] demon-
strated the presence of bufalin derivatives in the eye lenses of several
mammalian species and proposed a role for these compounds in
cataract formation. Sich et al. [31] reported that human plasma and
bovine adrenals contain material which cross-reacts with an antibody
against a plant-derived bufadienolide, proscillaridin A. In 1996 Hilton
and co-workers [32] mass-spectrometrically identiﬁed a bufadieno-
lide compound in human placentae.
4. Marinobufagenin
At least one of the circulating mammalian CTS is a bufadienolide,
marinobufagenin (MBG) [23]. MBG emerged as a candidate CTS based
on the in vitro studies which demonstrated that this steroid at low
concentrations induces vasoconstriction in isolated human blood
vessels and exhibits higher, as compared to ouabain, afﬁnity to α1
isoform of the Na/K-ATPase, an exclusive sodium pump isoform in
renotubular epithelium [14,33,34]. Normotensive human subjects on a
high NaCl diet exhibit elevations in plasma levels and renal excretion of
MBG [35]. In normotensive rats and dogs plasma MBG was stimulated
by acute plasma volume expansion and by chronic administration of a
high NaCl diet [36–39]. Increased production of MBG occurs in volume-
expanded states, such as essential hypertension, primary aldosteronism,
chronic renal failure [40], congestive heart failure [41], and pregnancy
[42,43]. Elevated levels of MBG in plasma and placenta are observed in
preeclampsia [42,44]. In hypertensive DS and in pregnant rats with
hypertension, induced by NaCl supplementation,monoclonal anti-MBGantibody reduced blood pressure and increased activity of the sodium
pump in the vasculature [43]. Recently, Komiyama et al. [45] puriﬁed
MBG and telocinobufagin, a possible MBG precursor from human
plasma and found that levels of TCB and MBG were signiﬁcantly
elevated in plasma of uremic patients. Subsequently, the same group
demonstrated thatmurine adrenocortical Y1 cells elaborateMBGand its
conjugated form, marinobufotoxin [46].
5. Cardiotonic steroids and regulation of sodium excretion
Before identiﬁcation of individual CTS in the mammalian tissues, it
had been demonstrated that the endogenous CTS are capable of
substantially inhibiting renal Na/K-ATPase activity [47]. Three potential
mechanisms may be offered to describe how low nanomolar or
subnanomolar concentrations of CTS present in mammalian plasma
promote natriuresis via interactionwith renotubular Na/K-ATPase. First,
circulating concentrations of MBG have been shown to signiﬁcantly
inhibit Na/K-ATPase activity in rat renal tissue despite the rodent α1
subunit being known to have decreased sensitivity to most cardiotonic
steroids [39,48]. InDSand in thenormotensive Sprague–Dawley rats, the
natriuretic responses to acute and chronic NaCl loadingwere associated
with substantial elevation in plasma concentration and renal excretion
of MBG, and in vivo administration of anti-MBG antibody reduced renal
sodium excretion and increased activity of renal Na/K-ATPase [49,50].
Some of thismay be related to the particular intracellular architecture of
the Na/K-ATPase in renal tissues. Na/K-ATPase partially puriﬁed from
renal membranes under “gentle” conditions, including pretreatment
with moderate concentration of SDS [50], as well as a preparation of
membrane-bound Na/K-ATPase without detergent, but with further
application of ionophore alamethicin [48]displays a biphasic response to
MBG inhibitiondespite the exclusive presenceofα1Na/K-ATPase in this
preparation [48,50]. Importantly, under these conditions, rat renalNa/K-
ATPase exhibits high afﬁnity Ki for the interaction with MBG and with
endogenousMBG-immunoreactivematerial puriﬁed fromurine of NaCl-
loaded DS [48]. Moreover, when intact renal membrane vesicles were
pretreatedwith gradually increasing concentrations of SDS, the biphasic
nature of MBG inhibitory curve gradually changed to a monophasic
exhibitinga singleKi (Fedorova, unpublishedobservation). This suggests
that a degree of polymerization of Na/K-ATPaseα-1 subunits (dimers or
tetramers) or some other membrane proteins (e.g., the γ subunit of the
Na/K-ATPase) can modulate the Na/K-ATPase responsiveness to some
CTS, including MBG.
CTS may interact with the other endogenous natriuretic hormones,
such as natriuretic peptides. Thus, low concentrations of α-hANP, via
cGMP/PKG-dependent mechanism, increase sensitivity of renal Na/K-
ATPase to MBG, but reduce MBG-sensitivity of vascular sodium pump
[51]. Thepotential importanceof such interaction couldbe illustrated by
the results of an experiment in which we compared blood pressure,
renal sodium excretion, activity of the sodium pump in aorta and renal
medulla, and levels of MBG, ANP, and cGMP in salt-loaded DS and
Sprague–Dawley rats [52]. In this experiment, NaCl loading elicited
increases in plasma ANP and in renal cGMP excretion in normotensive
Sprague–Dawley rats, but not in DS. NaCl loading produced sustained
elevations in renal MBG excretion in both DS and Sprague–Dawley rats.
While in NaCl-loaded DS SBP rose and aortic sodium pump was
inhibited, in Sprague–Dawley rat blood pressure and activity of aortic
sodium pump did not change. NaCl-loaded Sprague–Dawley rats
excreted twice as much sodium as DS, and in Sprague–Dawley rats
renal sodium pump was inhibited more than that in DS. Thus, in NaCl-
loaded normotensive and salt-sensitive rats, a comparable MBG
response is associated with preferential inhibition of the sodium
pump in the kidney and in vascular smooth muscle, respectively,
resulting in an adaptive natriuresis in Sprague–Dawley rats, but sodium
retention and pressor response in DS [52]. The lack of ANP response to
NaCl loading in DS appears to be one likely factor underlying different
patterns of Na/K-ATPase inhibition in two strains of rats.
Fig. 1. Transient response of endogenous ouabain precedes sustained increase in MBG
excretion during high NaCl intake. Similar patterns of renal excretion of endogenous
cardiotonic steroids during chronic NaCl loading of Dahl-S rats (administration of 8%
NaCl diet) (A and B) and subacute dietry NaCl supplementation of normotensive human
subjects (280 vs. 50 mmol NaCl per day) (C and D). By one-way ANOVA and Newman–
Keuls test: *Pb0.05; **Pb0.01 vs. day 0. Adapted from references 50 and 35.
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induced endocytosis of the Na/K-ATPase in kidney tissues. In
chronically NaCl-loaded Sprague–Dawley rats, renal MBG excretion
was signiﬁcantly elevated and anti-MBG antibody reduced natriuresis
and restored sodium pump activity in the renal cortex [39]. The same
study demonstrated that in addition to the direct inhibition of the Na/
K-ATPase, MBG is capable to exhibit its natriuretic effects via
internalization of the sodium pump in the proximal tubule [39]. The
endocytosis of the proximal tubular Na/K-ATPase induced by
CTS has been shown to proceed through clathrin coated pits and
require PI(3)K activation as well as the plasmalemmal pump being in
the context of caveolae, as well as signaling through the Src–EGFR
pathway [53,54]. Further work demonstrated that CTS can induce
decreases in the apical expression of one of the plasmamembraneNa+/
H+ exchanger, NHE3 [55,56]. Taken together, these data suggest that
increases in the circulating levels ofMBGaccompany salt loadingwhich,
in turn, may induce decreases in both basolateral and apical sodium
transport in the proximal tubule through both the classical or ionic
signaling mechanism and the more recently described Na/K-ATPase-
Src-EGFR pathway.
6. Endogenous ouabain and marinobufagenin in Dahl
salt-sensitive rats
Lewis Dahl proposed the existence of a prohypertensive
natriuretic hormone based on experiments with an inbred strain
of rats which develop progressive hypertension on a high NaCl
intake [57], i.e., in DS. Our laboratory studied CTS in this model, and
demonstrated that on a high NaCl diet (8% NaCl) DS exhibited a
transient rise in the levels of EO which was followed by a
progressive increase in plasma concentration and renal excretion
of MBG which paralleled elevation of the blood pressure [50]. When
DS with established hypertension were administered anti-MBG
antibody, blood pressure markedly decreased, while anti-ouabain
antibody did not exert such an effect [50]. Therefore, elevated levels
of MBG contributed to the maintenance of high blood pressure in
this genetic form of NaCl sensitive hypertension.
When central and peripheral levels of EO andMBGwere compared
in both chronically and acutely NaCl-loaded DS the responses of both
substances exhibited similar patterns, and transient EO response
preceded a more sustained increase in MBG excretion [13,50] (Fig. 1A,
B). Following acute NaCl loading, levels of EO in the amygdala,
hippocampus, pituitary, adrenals and plasma exhibited a transient
peak responsewhich was followed by a sustained rise in plasma levels
and renal excretion of MBG [58]. Such a pattern suggested that a
causative relationship might exist between an acute EO response and
a sustained elevation in MBG, i.e., that brain EO could trigger MBG
production. In accord with this hypothesis, pretreatment of the
acutely NaCl-loaded with anti-MBG antibodies did not attenuate the
EO response, but prevented NaCl-induced blood pressure increase
[58]. In the same experiment, pretreatment of NaCl-loaded DS with
anti-ouabain antibody markedly decreased NaCl-induced renal MBG
excretion [58].
Considering that, in previous studies from the laboratories of
Takahashi and Leenen [17,18], activation of RAAS was shown to be
implicated in the response of brain EO to high NaCl, we hypothesized
that brain RAAS may be a factor linking central (EO) and peripheral
(MBG) CTS. The effects of acute NaCl loading on blood pressure,
central and peripheral EO, on central and adrenal ATII, on plasma
norepinephrine and MBG, and Na/K-pump in renal medulla were
investigated in 10 week old DS [49]. NaCl loading induced transient
peak increases of EO in the hippocampus and pituitary followed by a
transient increase in pituitary ATII, increases in plasma NE and
adrenocortical ATII levels, a sustained increase in MBG excretion, a
45% inhibition of the renal Na/K-pump, and a 35 mmHg rise in arterial
pressure [49,58]. In these experiments, pretreatment of rats with anti-ouabain or anti-MBG polyclonal antibodies prevented the NaCl-
induced pressor response and renal Na/K-pump inhibition. Anti-
ouabain antibody pretreatment also prevented the increases in
pituitary and adrenal ATII, and reduced MBG production. Anti-MBG
antibody, in contrast, did not affect levels of central EO or ATII. In the
primary culture of adrenocortical cells from DS, 1 nmol/L ATII, in a
losartan-sensitive manner, doubled MBG production [49]. Thus, in
response to NaCl loading, brain EO stimulated adrenocortical MBG via
AT1 receptor signaling, and MBG inhibited the renal Na/K-pump and
elevated blood pressure, i.e., it behaved like a natriuretic hormone.
This sequence of events is schematically presented in Fig. 1.
Subsequently, it has been demonstrated that intrahippocampal
administration of an extremely low dose of ouabain to DS mimics
effects of NaCl loading including activation RAAS in the hypothal-
amus and adrenal cortex, increase in the adrenocortical levels of
MBG, inhibition of the sodium pump in vasculature and in the
kidney, and pressor and natriuretic responses [58]. Importantly, in
this experiment, in vivo peripheral administration of anti-MBG
antibody reversed the above effects induced by central administra-
tion of ouabain [58].
Although relevance of this scenario to pathogenesis of human
hypertension remains to be proven, in NaCl-loaded normotensive
human subjects [35] renal excretion of CTS exhibits a pattern similar
to that observed in NaCl-loaded DS [50], i.e., a transient increase in
renal excretion of EO precedes a more sustained increase in the
excretion of MBG (Fig. 2).
Several studies analyzed mechanisms which could link NaCl
loading/sodium retention to activation of brain EO. Leenen and
coworkers [59] demonstrated in rats that an increase in cerebrospinal
Fig. 2. Interactions between brain endogenous ouabain, renin–angiotensin system, and
marinobufagenin in pathogenesis of NaCl-sensitive hypertension. In NaCl-loaded Dahl
salt-sensitive rats, in the presence of impaired renal sodium transport, sodium
retention stimulates endogenous ouabain in the hippocampus, hypothalamus and
pituitary. Brain endogenous ouabain stimulates renin–angiotensin system in the
hypothalamus and pituitary, and activates sympathetic nervous system. These events
stimulate renin–angiotensin system in the adrenal cortex, and activate adrenocortical
production of marinobufagenin (MBG). MBG, a natriuretic and a vasoconstrictor, is
produced with a primarily adaptive aim, to induce natriuresis via inhibition of
renotubular Na/K-ATPase. An excessive MBG elaboration, however, induces a
maladaptive effect and leads to the inhibition of the Na/K-ATPase in vascular smooth
muscle cells and potentiates vasoconstriction.
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ions in the brain enter the intracellular space via epithelial sodium
channels [60], which is modulated by central mineralocorticoid
receptors [61]. Accordingly, Gabor and Leenen [62] demonstrated in
Wistar rats that immunoneutralization of brain EO prevented the
potentiating effect of exogenously administered aldosterone on
pressor response induced by central administration of sodium
chloride. Some data, however, suggest that brain-speciﬁc Nax rather
than epithelial sodium channels are involved in this process [63].
Importantly, in DS, NaCl-induced increase in the concentration of
sodium in cerebrospinal ﬂuid may be dependent on the altered
properties of the Na/K-ATPase in the chorioid plexus [64]. Thus, in DS
an abnormal function of the sodium pump is important not only for
renal sodium retention [65], but also for triggering of NaCl-induced
EO-dependent central mechanisms of establishment of hypertension.
7. Endogenous ouabain and adducin paradigm
Despite lack of evidence for natriuretic activity of EO, several lines
of evidence suggest prohypertensive role of EO, including induction of
hypertension in ouabain-treated rodents [66,67] and elevation of EO
levels in patients with essential hypertension [68]. In addition to EO
contributing to hypertension acting as a central mediator, two other
mechanisms, the “Adducin paradigm,” and the existence of highly
sensitive ouabain binding sites in vascular smooth muscle were
proposed to link the peripheral effects of EO to vasoconstriction in
hypertension.
In Milan hypertensive rats increased levels of EO in the presence of
a mutation of a cytoskeletal protein, adducin, are associated with
heightened expression and activity of the Na/K-ATPase in the
renotubular epithelium [69,70]. The increase in renal sodium pump
activity in Milan hypertensive rats occurs due to an increase of the
resident time of the Na/K-ATPase in the cellular membrane [70–72].
This effect of EO has beenmimicked by chronic infusion of low dose of
ouabain to normotensive rats which doubled plasma ouabain levels,
rose the blood pressure and increased levels of α1/β1 Na-K-ATPasesubunits, Src and EGFR in isolated caveolae membranes along with
activation of ERK1/2 [70]. It is believed that EO exhibits these effects
via interaction with a fraction of ouabain-sensitive sodium pumps
localized in the caveolae of renotubular cells [70]. Accordingly,
administration of an ouabain antagonist Rostafuroxin (PST2238), a
digitoxin derivative, to Milan hypertensive rats antagonized the
interaction of EO and adducin on the renal sodium pump, lowered the
blood pressure and normalized EO-induced up-regulation of Na/K-
ATPase in the renal medulla [70,73]. In agreement with the above
scenario, hypertensive patients with polymorphisms of the adducin
gene also exhibit altered renal sodium reabsorption [74]. Recently,
Manunta et al. [75] have demonstrated that saline loading produces
renal sodium retention in the hypertensives with elevated plasma EO
levels and mutant adducin.
Elevated levels of EO can also elevate blood pressure via inhibition of
ouabain-sensitiveα2 Na/K-ATPase and promoting Ca2+ entry via Na+/
Ca2+exchanger in vascular smoothmuscle [67,76]. Thus, thegenetically
engineered mice that express ouabain-resistant α2 Na/K-ATPase,
unlike control mice with more ouabain-sensitive sodium pumps, do
not increase blood pressure following chronic administration of
ouabain [67]. Vascular smoothmuscle from thesemicewith ouabain-
insensitive α2 sodium pumps is insensitive to the pressor effect of
ouabain [77]. Moreover, genetically engineered mice which have
reduced expression of α2 (but not α1) Na/K-ATPase become
hypertensive and their arteries exhibit enhanced vascular tone in
vitro [76].
8. Marinobufagenin and ﬁbrosis
Growing evidence suggests that contribution of CTS to pathogen-
esis of hypertension is not limited to involvement of these hormones
in the mechanisms of vasoconstriction and impaired renal sodium
excretion. Discovery of signaling functions of the sodium pump and
identiﬁcation of speciﬁc mechanisms underlying effects of low
concentrations of CTS on growth, development, and apoptosis add a
new dimension to understanding of pathophysiological roles of these
hormones [23]. Most recent ﬁndings indicate that CTS are also
implicated in themechanisms of development of ﬁbrosis. Several lines
of experimental evidence suggest that the classical i.e. “ionic
mechanism” might not be sufﬁcient to explain the effects of CTS on
the Na/K-ATPase both in vitro and in vivo. Thus, the effects of CTS on
the phosphorylation of key signaling proteins such as the EGFR can be
observed in cell free systems where changes in [Na] are essentially
excluded [78]. The positive evidence supporting the alternative or
“signaling” function for the Na/K-ATPase derived from several studies
can be summarized as follows. The Na/K-ATPase involved in signaling
through Src and the EGFR resides in caveolae and does not appear to
actively pump sodium or potassium [79]. Exposure of several different
cell types to CTS induce rapid phosphorylation of the EGFR in an Src-
dependent manner. The phosphorylation pattern for the EGFR is
distinctly different than that observed when EGFR induces autopho-
sphorylation of this protein [80,81]. In addition to the EGFR, other
signaling proteins appear to be recruited including phospholipase C
(PLC), TRP proteins, PI(3)K and several isoforms of protein kinase C
(PKC) [54,78,82–87]. The caveolar Na/K-ATPase binds closely with Src
andmaintains Src in an inactive form, and binding of CTS to the Na/K-
ATPase induces a conformation change which alters the relationship
between the Na/K-ATPase and Src and allows Src to become activated.
This active Src is then able to phosphorylate other proteins [87].
Notably, the binding of CTS to the plasmalemmal Na/K-ATPase
induces the endocytosis of the CTS-Na/K-ATPase-Src-EGFR complex
[39,53,54,88]. CTS binding to the Na/K-ATPase produces elevation in
cellular ROS which is dependent on the function of RAS [89]. The
downstream biochemical (e.g., activation of ERK) and physiological
(e.g., increases in cytosolic Ca) consequences of CTS binding to the
Na/K-ATPase can be prevented by ROS scavenging [83,89–91].
Fig. 3. Salt, hypertension and renal failure. Trade off of CTS effects? The schema
illustrates how CTS may be the molecular link explaining how long exposure to a high
salt diet may produce hypertension and cardiovascular disease. Speciﬁcally, we propose
that the proﬁbrotic effects of CTSmay, as a trade off formaintaining sodiumhomeostasis,
initially sub-clinically injure the renal parenchyma and in this manner, shift the
relationship between blood pressure and sodium. Because of this, patients might be
expected to develop hypertension which may, in and of itself, increase circulating CTS
levels and synergistically injure organs including the heart and kidney.
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from a group of experiments performed in our laboratories. First,
we noted that experimental renal failure produced a tremendous
amount of cardiac ﬁbrosis in both rat and mouse [91–93]. The
cardiomyopathy associated with human renal failure is also
complicated by considerable ﬁbrosis, although ﬁbrosis, in general,
does appear to develop much faster in the rodent models. Active
immunization against an MBG-albumin conjugate which resulted in
a high antibody titer, as well as reduction of circulating levels of
MBG by adrenalectomy, prevented cardiac ﬁbrosis seen with
experimental renal failure and treatment of animals with an
infusion of MBG which achieved similar plasma levels of MBG as
seen with experimental renal failure caused a similar degree of
cardiac ﬁbrosis [91,92]. Activation of Na/K-ATPase signaling as
evidenced by increases in both Src and MAPK phosphorylation in
cardiac tissue was also seen along with the cardiac ﬁbrosis [91,92].
Based on these in vivo results, we examined whether MBG and
other CTS had effects on ﬁbroblasts grown in culture. First, we saw
that both MBG and other CTS (e.g., ouabain, digoxin) caused
ﬁbroblasts grown to conﬂuence to increase proline incorporation as
well as collagen production, the latter measured with Western blot.
This was, again, coincident with evidence of Na/K-ATPase signaling in
that Src and MAPK activation could be observed as well as the
effectiveness of ROS scavenging and Src inhibition in preventing the
increases in proline incorporation and collagen production [92].
Increases in mRNA for collagen following exposure to MBG was also
noted [92]. Interestingly, we did not note increases in TGF beta or
SMAD proteins, but antagonism of the TGF beta system with
SB421542 did block MBG induced stimulation of collagen production
[92]. Based on previous work in dermal ﬁbroblasts demonstrating that
Fli-1 is a negative regulator of collagen synthesis [94], we chose to
examine whether MBG signaling altered the expression of Fli-1. We
noted that MBG induced decreases in Fli-1 expression in several types
of ﬁbroblasts (cardiac, renal and dermal), and we further noted that
the decreases in Fli-1 appeared to be necessary for MBG to induce
increases in collagen [95]. Further studies demonstrated that MBG
appears to induce translocation of PKCdelta from the cytosol to the
nucleus in a PLC-dependant manner, and that the translocation of
PKCdelta appeared to result in the phosphorylation and subsequent
degradation of Fli-1 [95].
Because of these results as well as controversy as to how
mineralocorticoid antagonists ameliorated cardiac ﬁbrosis, we exam-
ined the effects of spironolactone and its major metabolite, canre-
none, in a series of in vitro and in vivo studies. We observed that both
spironolactone and canrenone could attenuate MBG induced
increases in collagen production by cardiac ﬁbroblasts, a ﬁnding
which was corroborated in vivo by marked attenuation of the cardiac
ﬁbrosis caused by experimental renal failure with spironolactone
treatment [96]. However, in vitro, we could not see a substantial effect
of aldosterone on cardiac collagen production. That said, we did
observe that both spironolactone and canrenone prevented MBG
signaling. Moreover, both spironolactone and canrenone appeared to
act as competitive inhibitors of CTS binding to the Na/K-ATPase [96], a
ﬁnding ﬁrst proposed by Finnotti and Palatini [97–99]. Based on these
ﬁndings, it appears that CTS signaling may be a fertile area for
therapeutic drug development.
As mentioned above, the effects of MBG (and other CTS) are not
speciﬁc for cardiac ﬁbroblasts. In fact, renal ﬁbroblasts have a very
similar response as cardiac ﬁbroblasts [100]. This suggested that MBG
might potentially be involved in renal ﬁbrosis. Moving back to the in
vivo model of MBG infusion, we observed that MBG administration
was associated with increases in renal collagen content. We also
observed that Snail, a transcription factor known to be involved in
epithelial–mesenchymal transformation (EMT), appeared to be up-
regulated with MBG infusion. In cell culture, LLC-PK1 cells could be
induced to undergo EMT by exposure to MBG in a dose- and time-dependent fashion [100]. This suggests the following “trade off”which
might explain why high salt diet appears to lead to hypertension and
renal functional impairment over a long period of time in humans
(Fig. 3).
In addition to their potential role in uremic cardiomyopathy and
renal ﬁbrosis, CTS-induced synthesis of collagen may be one of the
factors contributing to vascular dysfunction in preeclampsia. Recently,
we demonstrated that development of preeclampsia is associated
with elevated levels of MBG in placentae, and decreased levels of Fli-1
and markedly increased levels of collagen-1 in umbilical arteries
[101]. Notably, in the in vitro experiments, rings of umbilical arteries
from patients with preeclampsia, in the presence of unaltered
responsiveness to endothelin-1, exhibited a marked reduction in the
responsiveness to vasorelaxant action of sodium nitroprusside, as
compared to that in the vessels obtained from subjects with
uncomplicated pregnancies [101].
Although much of our discussion has revolved around the “newer”
signaling function of the pump, i.e., the signal transduction mediated
through its caveolar associationwith Src, the EGFR and other signaling
partners, the classical concept that CTS signal by inhibiting the
pumping function of the Na/K-ATPase is still relevant. For example, it
is well known that red blood cells of patients with end stage renal
disease or preeclampsia, as well as NaCl-loaded DS, have decreases in
Na/K-ATPase activity which can be reversed by incubation, ex vivo,
with antibodies to MBG or with Digibind, an ovine digoxin antibody
which interacts with CTS [43,50,102]. From these and other data
which have been summarized in several recent reviews, we would
propose that both the classical and alternative pathways may work
both in parallel as well as synergistically to effect physiological
consequences of CTS binding to the Na/K-ATPase.9. Conclusions
A number of studies have now validated the initial intuition of
deWardener, Blaustein and the others [2–7], and possibly extended
it beyond what was initially conceived. In fact, it is becoming clear
that several endogenous factors including EO, MBG, natriuretic
peptides interact with each other on multiple levels and in complex
manner and together account for the effects of the putative
natriuretic hormone. The role of CTS viewed only as natriuretic
hormones is an incomplete view. The recently described “signaling”
function of the Na/K-ATPase has presented a number of potential
therapeutic targets for existing medications as well as for
pharmacological development addressing diseases ranging from
hypertension to progressive renal failure.
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